36778-15-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Isothiazolecarboxylic acid, 5-nitrois used as a key intermediate in the synthesis of pharmaceuticals for its potential role in the development of new drugs. Its unique chemical structure allows for the creation of novel therapeutic agents that could address various medical conditions.
Used in Research and Development:
In the realm of scientific research, 3-Isothiazolecarboxylic acid, 5-nitroserves as a valuable compound for exploring new chemical reactions and understanding the properties of isothiazole derivatives. It aids researchers in advancing knowledge in organic chemistry and medicinal chemistry.
Used in Chemical Compound Production:
3-Isothiazolecarboxylic acid, 5-nitrois utilized as a building block in the production of certain types of chemical compounds. Its presence in these compounds can impart specific characteristics that are beneficial for various applications, such as enhancing stability or improving reactivity.

InChI:InChI=1/C4H2N2O4S/c7-4(8)2-1-3(6(9)10)11-5-2/h1H,(H,7,8)

Upstream product

• 36778-16-2 3-methyl-5-nitroisothiazole 

Downstream Products

• 36778-14-0 5-nitro-isothiazole-3-carbonyl chloride 
• 481687-38-1 5-nitro-N-para-[4-(trifluoromethyl)phenoxy] phenyl-isothiazole-3-carboxamide 
• 59038-02-7 (5-nitroisothiazol-3-yl)(4-methylpiperazin-1-yl)methanone 
• 1094070-50-4 C₅H₄N₂O₄S 

Relevant academic research and scientific papers

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.

New geldanamycin derivatives with anti Hsp properties by mutasynthesis

Mutasynthetic supplementation of the AHBA blocked mutant strain of S. hygroscopicus, the geldanamycin producer, with 21 aromatic and heteroaromatic amino acids provided new nonquinoid geldanamycin derivatives. Large scale (5 L) fermentation provided four new derivatives in sufficient quantity for full structural characterisation. Among these, the first thiophene derivative of reblastatin showed strong antiproliferative activity towards several human cancer cell lines. Additionally, inhibitory effects on human heat shock protein Hsp90α and bacterial heat shock protein from H. pylori HpHtpG were observed, revealing strong displacement properties for labelled ATP and demonstrating that the ATP-binding site of Hsps is the target site for the new geldanamycin derivatives.

Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers

SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), also known as Brahma homologue (BRM), is a Snf2-family DNA-dependent ATPase. BRM and its close homologue Brahma-related gene 1 (BRG1), also known as SMARCA4, are mutually exclusive ATPases of the large ATP-dependent SWI/SNF chromatin-remodeling complexes involved in transcriptional regulation of gene expression. No small molecules have been reported that modulate SWI/SNF chromatin-remodeling activity via inhibition of its ATPase activity, an important goal given the well-established dependence of BRG1-deficient cancers on BRM. Here, we describe allosteric dual BRM and BRG1 inhibitors that downregulate BRM-dependent gene expression and show antiproliferative activity in a BRG1-mutant-lung-tumor xenograft model upon oral administration. These compounds represent useful tools for understanding the functions of BRM in BRG1-loss-of-function settings and should enable probing the role of SWI/SNF functions more broadly in different cancer contexts and those of other diseases.